Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Home > Insider Trading > Filing (0000914190-21-000405)

Filing Details

Accession Number:
0000914190-21-000405
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-11-16 16:51:43
Reporting Period:
2021-11-12
Accepted Time:
2021-11-16 16:51:43
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
842023 Bio-Techne Corp TECH Biological Products, (No Disgnostic Substances) (2836) 411427402
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1270905 David Norman Eansor 8100 Southpark Way, A-8
Littleton CO 80120		 President-Protein Sciences No Yes No No
Reported Non-Derivative Transactions
Show Other Fields >>
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-11-12 27,159 $125.05 28,477 No 4 M Direct
Common Stock Disposition 2021-11-12 700 $504.09 27,777 No 4 S Direct
Common Stock Disposition 2021-11-12 200 $504.78 27,577 No 4 S Direct
Common Stock Disposition 2021-11-12 300 $502.99 27,277 No 4 S Direct
Common Stock Disposition 2021-11-12 537 $504.14 26,740 No 4 S Direct
Common Stock Disposition 2021-11-12 400 $505.01 26,340 No 4 S Direct
Common Stock Disposition 2021-11-12 4,054 $502.77 22,286 No 4 S Direct
Common Stock Disposition 2021-11-12 9,043 $503.61 13,243 No 4 S Direct
Common Stock Disposition 2021-11-12 8,989 $504.39 4,254 No 4 S Direct
Common Stock Disposition 2021-11-12 2,535 $505.49 1,719 No 4 S Direct
Common Stock Disposition 2021-11-12 401 $506.24 1,318 No 4 S Direct
Common Stock Acquisiton 2021-11-16 799 $125.05 2,117 No 4 M Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
Reported Derivative Transactions
Show Other Fields >>
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options (Right to Buy) Disposition 2021-11-12 27,159 $0.00 27,159 $125.05
Common Stock Stock Options (Right to Buy) Disposition 2021-11-16 799 $0.00 799 $125.05
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
799 2024-08-09 No 4 M Direct
0 2024-08-09 No 4 M Direct
Reported Derivative Holdings
Show Other Fields >>
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Stock Options (Right to Buy) $177.32 2025-08-08 13,550 13,550 Direct
Common Stock Stock Options (Right to Buy) $177.32 2025-08-08 18,066 18,066 Direct
Common Stock Restricted Stock Units $0.00 3,151 3,151 Direct
Common Stock Stock Options (Right to Buy) $190.41 2026-08-07 15,948 15,948 Direct
Common Stock Stock Options (Right to Buy) $190.41 2026-08-07 21,265 21,265 Direct
Common Stock Restricted Stock Units $0.00 2,575 2,575 Direct
Common Stock Stock Options (Right to Buy) $267.87 2027-08-05 11,488 11,488 Direct
Common Stock Stock Options (Right to Buy) $267.87 2027-08-05 15,318 15,318 Direct
Common Stock Stock Options (Right to Buy) $267.87 2027-08-05 24,975 24,975 Direct
Common Stock Stock Options (Right to Buy) $267.87 2027-08-05 24,975 24,975 Direct
Common Stock Restricted Stock Units $0.00 1,556 1,556 Direct
Common Stock Stock Options (Right to Buy) $481.82 2028-08-06 6,080 6,080 Direct
Common Stock Stock Options (Right to Buy) $481.82 2028-08-06 8,107 8,107 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2025-08-08 13,550 13,550 Direct
2025-08-08 18,066 18,066 Direct
3,151 3,151 Direct
2026-08-07 15,948 15,948 Direct
2026-08-07 21,265 21,265 Direct
2,575 2,575 Direct
2027-08-05 11,488 11,488 Direct
2027-08-05 15,318 15,318 Direct
2027-08-05 24,975 24,975 Direct
2027-08-05 24,975 24,975 Direct
1,556 1,556 Direct
2028-08-06 6,080 6,080 Direct
2028-08-06 8,107 8,107 Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.78 to $504.535, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $502.62 to $503.33, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.77 to $504.745, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $504.97 to $505.11, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $502.11 to $503.10, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.11 to $504.107, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $504.13 to $505.11, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $505.13 to $506.07, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $506.20 to $506.275, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  10. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
  11. Fully exercisable.
  12. Options to purchase 4,517 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 4,516 shares vest on each of 8/8/2021 and 8/8/2022.
  13. Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  14. Options to purchase 5,317 shares vest on 8/7/2020 and options to purchase 5,316 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023.
  15. Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  16. Options to purchase 3,830 shares vest on each of 8/5/2021 and 8/5/2022 and options to purchase 3,829 shares vest on each of 8/5/2023 and 8/5/2024.
  17. Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.
  18. Options to purchase 8,325 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.
  19. Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  20. Options to purchase 2,027 shares vest on each of 8/6/2022, 8/6/2023 and 8/6/2024 and options to purchase 2,026 shares vest on 8/6/2025.
Insider Monkey Quarterly Strategy
+336.2% Insider Monkey Quarterly Strategy
+144.8% Benchmark50% S&P 500 ETF and 50% Russell 2000 ETF
300%
200%
100%
Subscribe Now

Returns since its inception in May 2014 (through November 14th, 2024)